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To evaluate the capacity of multivariable prediction of preeclampsia during pregnancy,
based on detailed routinely collected early pregnancy data in nulliparous women.
Design and setting
A population-based cohort study of 62 562 pregnancies of nulliparous women with deliveries
2008–13 in the Stockholm-Gotland Counties in Sweden.
Methods
Maternal social, reproductive and medical history and medical examinations (including
mean arterial pressure, proteinuria, hemoglobin and capillary glucose levels) routinely col-
lected at the first visit in antenatal care, constitute the predictive variables. Predictive models
for preeclampsia were created by three methods; logistic regression models using 1) pre-
specified variables (similar to the Fetal Medicine Foundation model including maternal fac-
tors and mean arterial pressure), 2) backward selection starting from the full suite of vari-
ables, and 3) a Random forest model using the same candidate variables. The performance
of the British National Institute for Health and Care Excellence (NICE) binary risk classifica-
tion guidelines for preeclampsia was also evaluated. The outcome measures were diagno-
sis of preeclampsia with delivery <34, <37, and�37 weeks’ gestation.
Results
A total of 2 773 (4.4%) nulliparous women subsequently developed preeclampsia. The pre-
specified variables model was superior the other two models, regarding prediction of pre-
eclampsia with delivery <34 and <37 weeks, both with areas under the curve of 0.68, and
sensitivity of 30.6% (95% CI 24.5–37.2) and 29.2% (95% CI 25.2–33.4) at a 10% false
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positive rate, respectively. The performance of these customizable multivariable models at
the chosen false positive rate, was significantly better than the binary NICE-guidelines for
preeclampsia with delivery <37 and�37 weeks’ gestation.
Conclusion
Multivariable models in early pregnancy had a modest performance, although providing
advantages over the NICE-guidelines, in predicting preeclampsia in nulliparous women.
Use of a machine learning algorithm (Random forest) did not result in superior prediction.
Introduction
Recent evidence suggests that the risk of the generally more severe preterm preeclampsia
(delivery <37 weeks) can be substantially reduced by prophylactic use of aspirin from early
pregnancy to a defined high-risk population [1, 2]. Delay in the diagnosis of preeclampsia fur-
ther contributes significantly to maternal morbidity and mortality [3–6]. Thus, accurate pre-
diction of preeclampsia to enable preventive treatment and optimised surveillance is an urgent
priority.
According to the National Institute for Health and Excellence’s (NICE) and other current
national guidelines clinical early pregnancy decision rules for detection of women at high-risk
of developing preeclampsia, are based on maternal and medical history risk factors [7–9].
These risk factors are evaluated individually without being incorporated into combined multi-
variable models, resulting in poor prediction, characterized by low sensitivity and specificity
[10–12].
Clinical risk prediction models with combined predictor variables, also including medical
examinations, have been developed in recent years and has led to improved detection rates
[13, 14]. The Fetal Medicine Foundation (FMF) has created predictive models using a limited
number of maternal factors with addition of mean arterial pressure (MAP) [15]. More com-
plex FMF models include various combinations of biophysical, such as uterine artery Doppler,
and biochemical markers, not routinely performed in antenatal care [10]. Since detection rates
and cut-off values have shown to vary between populations, depending on differences in
healthcare systems, incidence of disease and overfitting of the original model, the performance
of these models have to be validated in other populations [16–19]. It has been emphasized that
the cost-effectiveness of these more complex models has to be established before widespread
use in clinical practice [14, 20]. Evidence further suggests that when using a vast number of
clinical predictive variables and MAP in a model for low-risk nulliparous women, uterine
artery Doppler does not improve the predictive capacity for preeclampsia [13]. A recent sys-
tematic review points out the need for development of predictive models with the optimal
combination of simple maternal factors [14] and the predictors included in the FMF model do
not comprise all known maternal risk factors for preeclampsia [12].
Nulliparous women have higher risk of preeclampsia and the predictive capacity of both
clinical decision rules and multivariable models are better for parous than nulliparous women
[11, 20, 21]. Few predictive models have been designed for nulliparous women [14] and this
group would largely benefit from an improved screening. The performance of multivariable
maternal factor models with MAP compared to the NICE guidelines risk classification in nul-
liparous women has to be further explored.
Preeclampsia prediction in nulliparous women
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Swedish antenatal care is free of charge and almost all women attend [22]. Information on
well-recognised, less established and unknown risk factors for preeclampsia, including almost
all of the maternal characteristics variables incorporated in the FMF model and more, are col-
lected at the first visit. Construction of predictive models using this comprehensive range of
Swedish maternal health care data has not yet been performed In recent years, advanced pre-
diction techniques including Machine learning methods [23] (e.g., Random forest) [24] have
been implemented in medicine [25, 26]. These methods use data-driven approaches to select
maximized predictive models using objective criteria rather than relying on expert opinion,
and no assumptions of linearity or arbitrary cut-points are needed. These approaches also
enable consideration of a large number of candidate predictors and complex interactions are
possible to handle. To our knowledge, predictive models in early pregnancy for preeclampsia
using a machine learning method have not been performed to date.
Study objective
The objective was to create multivariable predictive models using three different methodologi-
cal approaches (a logistic regression models with pre-specified variables similar to the Fetal
Medicine Foundation model including maternal variables and MAP, a backward selection
model starting from the full suite of variables, and a Random forest model) and the NICE-
guidelines, to identify nulliparous women at increased risk of preeclampsia, using detailed rou-
tinely collected information from early pregnancy in a Swedish setting.
Material and methods
Setting
Data were derived from the Stockholm-Gotland Obstetric Cohort, a population-based data-
base with information automatically retrieved from the computerized medical record system
in the Stockholm-Gotland counties in Sweden. The database contains detailed, prospectively
collected demographic, medical, obstetrical and neonatal data from all antenatal, delivery and
postnatal care units in the region. Information is routinely entered into the medical records by
midwifes or physicians in a standardized way. Approximately one fourth of all 115 000 annual
births in Sweden occurs in the seven hospitals in the region.
Study population
Live-born births between January 1st, 2008 and December 31st, 2013 were included in the
cohort of 149 298 singleton pregnancies. The population was restricted to pregnancies of nul-
liparous women delivered from gestational week 22. Pregnancies of women without informa-
tion on gestational length or without notation of blood pressure before 15 weeks’ gestation
were excluded. The final study population included 62 562 pregnancies (Fig 1). We were also
interested in predicting preeclampsia in pregnancies without major anomalies and among
women not receiving aspirin, since this can alter the performance of the predictive models.
For sensitivity analysis, pregnancies with major fetal malformations or maternal use of aspirin
during pregnancy were excluded, giving a restricted population of 58 276 pregnancies (Fig 1).
Data sources
The pregnancies in the Stockholm-Gotland Obstetric Cohort were individually linked using
the person-unique national registration numbers with the National Patient Register [27] and
the Swedish Prescribed Drug Register [28]. The National Patient Register includes Interna-
tional Classification of Diseases (ICD) diagnoses on inpatient admissions and outpatient visits.
Preeclampsia prediction in nulliparous women
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The Swedish Prescribed Drug Register holds data on all prescribed substances, ATC-code
(Anatomical Therapeutic Chemical classification) and date of purchase for all dispensed drugs
in the outpatient population.
Study variables
Outcome. Diagnosis of preeclampsia was the key variable, classified according to the
Swedish version of ICD-10 codes (O140, O141, O149 or O15) by the responsible doctor during
pregnancy or at discharge, and was retrieved from the National Patient Register. Preeclampsia
was defined as hypertension (blood pressure�140 mmHg and/or diastolic blood pressure
�90 mmHg two times with an interval of at least 4 hours), combined with proteinuria (� 0.3
Fig 1. Flowchart of 149 298 included pregnancies of women who were delivering in the Stockholm-Gotland Counties of Sweden
2008–2013.
https://doi.org/10.1371/journal.pone.0225716.g001
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g/24 hours or 2+ on a dipstick testing) occurring after 20 weeks’ gestation. In order to fulfill
our definition of preeclampsia, there had to be one diagnosis in the inpatient register or two in
the outpatient register, where the date of the first diagnosis was used.
Accuracy of prediction of preeclampsia was quantified by detection rates (i.e. sensitivity) of
diagnosis of preeclampsia; 1) overall: during pregnancy, 2) early-onset: with delivery<34
weeks, 3) preterm: with delivery <37 weeks and 4) term: with delivery�37 weeks.
Candidate predictors. At the first visit to antenatal care, around gestational week 10, the
woman is interviewed about her social, reproductive and medical background, and medical
examinations are performed. The routinely collected information from this visit were included
in this study as 36 candidate predictors for preeclampsia in the predictive models, presented in
Table 1.
Gestational length was determined using the following hierarchy: a) date of embryo trans-
fer, b) early first or early second trimester ultrasound, c) date of last menstrual period, and d)
from postnatal assessment. Information on social factors (family situation and country of
birth), smoking, snuff and alcohol habits as well as reproductive history (parity, previous mis-
carriage or ectopic pregnancy, assisted reproduction and infertility duration) are self-reported.
Further, the women are interviewed about their medical history (including pre-existing
chronic diseases). The definition of diabetes included pre-gestational diabetes type I and II.
The collected information is registered in a standardized way either as tick boxes, pre-specified
options, or as numbers. Family history of hypertension or preeclampsia is however registered
as free text and two dichotomous variables (family history of hypertension and family history
of preeclampsia) were constructed.
Maternal BMI (kg/m2) was calculated from self-reported height and measured or self-
reported weight. Maternal blood pressure is measured by the midwife in supine position on
the right upper arm using manual blood pressure equipment with a cuff size appropriate for
arm circumference. Korotkoff V is used for diastolic blood pressure. The first recorded blood
pressure <15 weeks was collected. Mean arterial pressure (MAP), defined as: (systolic blood
pressure + (2 x diastolic blood pressure))/3, was calculated and used in the predictive models.
Capillary blood sampling for plasma glucose and haemoglobin, venous sampling for blood
group and urine dipstick test for protein is collected. All the candidate predictors were treated
as continuous or categorized as presented in Table 1.
Restricted population. Occurrence of major malformation was defined as any recorded
congenital anomaly in the National Patient Register (ICD-10 codes Q00–Q99), excluding
minor malformations not reported to the Register of Birth Defects [29]. Use of aspirin during
pregnancy was defined as purchased prescription of aspirin during pregnancy in the Swedish
Prescribed Drug Register (a prescription is needed for aspirin for the doses indicated during
pregnancy).
Statistical methods
Statistical analyses were done with STATA 12 (StataCorp, College Station, TX, USA) for uni-
variable and multivariable regression analyses. For Random Forest analyses, the statistical soft-
ware package R (version 3.4.4, R Foundation for Statistical Computing, Vienna, Austria) was
used. Chi-squared test and two sample t-test were used for comparing the variables in the
study population in women who did and did not develop preeclampsia. In order to maximize
the predictive power of our predictive models, we used three different multivariable statistical
methods:
Pre-specified variables model. In this multivariable regression model for nulliparous
women we used similar variables as in the FMF maternal factors and MAP model [11]. The
Preeclampsia prediction in nulliparous women
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Table 1. Predictive variables routinely collected at first visit to antenatal care in the study population of 62 562 nulliparous women.
Predictive variables No preeclampsia
n = 59 789
(95.6%)
Overall preeclampsia
n = 2 773
(4.4%)





Gestational length first examination, weeks a 9.6 (1.9) 9.6 (1.9) 0.022 9.3 (1.9) <0.001
Maternal age, years a 29.3 (5.0) 29.9 (5.3) <0.001 30.3 (5.8) <0.001
BMI, kg/m2 a 23.4 (4.0) 25.1 (4.9) <0.001 24.7 (5.1) <0.001
Missing (n) 2 066 92 11
Mean Arterial Pressure (MAP), mmHg a 81.5 (8.0) 86.3 (9.1) <0.001 86.7 (9.6) <0.001
Capillary glucose, mmol/L a 5.5 (1.1) 5.6 (1.1) <0.001 5.7 (1.2) 0.002
Missing (n) 4 905 238 45
Protein in urine, dipstick 0–3 a 0.03 (0.2) 0.05 (0.3) <0.001 0.06 (0.3) 0.001
Missing (n) 9 089 407 61
Hemoglobin (Hb), g/L a 127.8 (10.3) 129.5 (10.5) <0.001 130.0 (10.4) <0.001
Missing (n) 4 462 221 42
Previous miscarriage (n) a 0.23 (0.57) 0.26 (0.60) 0.017 0.25 (0.62) 0.537
Previous ectopic pregnancy (n) a 0.012 (0.12) 0.013 (0.13) 0.529 0.014 (0.13) 0.635
Infertility duration, years a 0.40 (1.2) 0.54 (1.5) <0.001 0.66 (1.8) <0.001
Family situation n (%) 0.241 0.298
Single 1 225 (2.05) 72 (2.60) 16 (3.22)
Living together with partner 54 996 (91.98) 2 533 (91.35) 455 (91.55)
Other 3 203 (5.36) 149 (5.37) 23 (4.63)
Missing (n) 365 (0.61) 19 (0.69) 3 (0.60)
Region of birth n (%) <0.001 0.164
Sweden 44 306 (74.10) 2 172 (78.33) 373 (75.05)
Nordic countries (except of Sweden) 951 (1.59) 41 (1.48) 5 (1.01)
Europe (except of Nordic countries) 4 496 (7.52) 154 (5.55) 31 (6.24)
Africa 1 891 (3.16) 109 (3.93) 27 (5.43)
North America 394 (0.66) 13 (0.47) 2 (0.40)
South America 1 003 (1.68) 36 (1.30) 8 (1.61)
Asia 5 912 (9.89) 187 (6.74) 43 (8.65)
Oceania 54 (0.09) 3 (0.11) 0 (-)
Missing (n) 782 (1.31) 58 (2.09) 8 (1.61)
Smoking 3 months before pregnancy n (%) 0.867 0.054
<10 5 173 (8.65) 237 (8.55) 27 (5.43)
�10 4 333 (7.25) 190 (6.85) 32 (6.44)
Missing (n) 361 (0.60) 16 (0.58) 4 (0.80)
Smoking at registration n (%) 0.128 0.213
<10 2 071 (3.46) 76 (2.74) 14 (2.82)
�10 371 (0.62) 21 (0.76) 5 (1.01)
Missing (n) 332 (0.56) 12 (0.43) 0 (-)
Snuff 3 months before pregnancy n (%) 2 142 (3.58) 110 (3.60) 0.288 20 (4.02) 0.610
Snuff at registration n (%) 624 (1.04) 35 (1.26) 0.271 4 (0.80) 0.586
Alcohol consumption 3 months before registration n (%) <0.001 0.004
� Once a week 20 226 (33.83) 929 (33.50) 149 (29.98)
> Once a week 9 485 (15.86) 349 (12.52) 61 (12.27)
Missing (n) 3 665 (6.13) 172 (6.20) 27 (5.43)
Alcohol consumption at registration n (%) 0.634 0.160
� Once a week 445 (0.74) 19 (0.69) 8 (1.61)
(Continued)
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included variables in the two models are specified in Table 2. For internal validation, we did a
10-fold cross-validation, using randomly allocated 90% of the data to generate a predictive
model, and estimation of the risk of preeclampsia is then applied to the remaining 10% of the
sample. This splitting procedure is repeated a large number of times and the performance of
the model is then summarized.
Backward selection model. To select the best variables for this model for each outcome,
we used backward selection on a multivariable logistic regression with an exclusion criterion
of p-value more than 0.2. We submitted the 36 candidate predictors described above to this
model-selection procedure. For internal validation, a 10-fold cross-validation was used.
Random forest model. We used Random forest [24], a machine learning method [23],
which is an ensemble method making use of multiple decision trees. We submitted the same
36 candidate predictors employed in the backward selection procedure in the Random Forest
Table 1. (Continued)
Predictive variables No preeclampsia
n = 59 789
(95.6%)
Overall preeclampsia
n = 2 773
(4.4%)





> Once a week 122 (0.20) 3 (0.11) 1 (0.20)
Missing (n) 3 655 (6.11) 162 (5.84) 29 (5.84)
Family history of preeclampsia n (%) 150 (0.25) 18 (0.65) <0.001 5 (1.01) 0.001
Family history of hypertension n (%) 10 034 (16.78) 634 (22.86) <0.001 116 (23.34) <0.001
Infertility n (%) 0.006 0.870
Without treatment 3 997 (6.69) 201 (7.25) 36 (7.24)
Ovary stimulation 885 (1.48) 48 (1.73) 9 (1.81)
IVF 3 979 (6.66) 225 (8.11) 35 (7.04)
Cardiovascular disease n (%) 780 (1.30) 49 (1.77) 0.037 8 (1.61) 0.578
Endocrine disease n (%) 2 983 (4.99) 174 (6.27) 0.002 34 (6.84) 0.066
Pre-existing diabetes n (%) 264 (0.44) 62 (2.24) <0.001 21 (4.23) <0.001
Thrombosis n (%) 417 (0.70) 16 (0.58) 0.454 2 (0.40) 0.434
Psychiatric disease n (%) 5 542 (9.27) 271 (9.77) 0.372 51 (10.26) 0.455
SLE n (%) 68 (0.11) 3 (0.11) 0.932 1 (0.20) 0.560
Epilepsy n (%) 367 (0.61) 18 (0.65) 0.816 3 (0.60) 0.973
Chronic hypertension n (%) 260 (0.43) 43 (1.55) <0.001 12 (2.41) <0.001
Mb Crohn/Ulcerous colitis n (%) 514 (0.86) 19 (0.69) 0.328 5 (1.01) 0.707
Lung disease or asthma n (%) 4 915 (8.22) 272 (9.81) 0.003 50 (10.06) 0.151
Chronic kidney disease n (%) 276 (0.46) 27 (0.97) <0.001 10 (2.01) <0.001
Hepatitis n (%) 486 (0.81) 22 (0.79) 0.911 7 (1.41) 0.137
Gynaecological disease or operation n (%) 11 329 (18.95) 528 (19.04) 0.903 102 (20.52) 0.370
Recurrent urinary tract infections n (%) 9 081 (15.19) 397 (14.32) 0.211 66 (13.28) 0.243
Blood group n (%) 0.124 0.032
0 21 039 (35.19) 930 (33.54) 147 (29.58)
A 23 782 (39.78) 1 117 (40.28) 199 (40.04)
AB 3 044 (5.09) 127 (4.58) 30 (6.04)
B 7 344 (12.28) 369 (13.31) 71 (14.29)
Missing (n) 4 580 (7.66) 230 (8.29) 50 (10.06)
a Mean at registration (standard deviation)
� Preeclampsia overall compared to no preeclampsia.
�� Preterm preeclampsia compared to no preterm preeclampsia (no preeclampsia and term preeclampsia).
https://doi.org/10.1371/journal.pone.0225716.t001
Preeclampsia prediction in nulliparous women
PLOS ONE | https://doi.org/10.1371/journal.pone.0225716 November 27, 2019 7 / 16
approach. For each tree, a bootstrap sample was drawn, from which the tree was built. In order
to get an unbiased estimate of the area under the receiver operating characteristic curve
(AUC), the Out-of-Bag samples were used when predicting the probabilities of the outcomes.
NICE-guidelines. In addition to the multivariable models described above, we created a
risk classification system based on the NICE-guidelines binary (high-risk: yes or no) clinical
decision rule. Having a high-risk for preeclampsia according to the NICE-guidelines for nul-
liparous women in early pregnancy include any of the following risk factors: Chronic kidney
disease, systemic lupus erythematosus, antiphospholipid syndrome (not included in our
NICE-guidelines model), type 1 or type 2 diabetes, chronic hypertension, age 40 or older, BMI
35 or more at registration, and family history of preeclampsia [9].
Missing values. To increase the power and minimise selection bias we used single-
chained imputation with mean values for missing observations for the variables with missing
information (Table 1).
AUC. The AUC for the three multivariable methods were calculated using bias corrected
bootstrap confidence intervals. The detection rate of preeclampsia at a 10% fixed false positive
rate (FPR) was calculated with a 95% confidence interval (CI) using the Clopper-Pearson
method.
Results
In the study population of 62 562 nulliparous women, 2 773 (4.4%) developed preeclampsia
during pregnancy. In total 216 (0.3%) developed preeclampsia with delivery <34 weeks, 497
(0.8%) developed preeclampsia with delivery <37 weeks and 2 276 (3.6%) developed pre-
eclampsia with delivery�37 weeks, respectively. Aspirin was used by 623 (1.1%) of the women
with non-anomalous pregnancies (Fig 1).
Table 2. Variables included in the pre-specified model and the corresponding similar variables included in the
Fetal Medicine Foundation’s (FMF) model with maternal characteristics and mean arterial pressure for nullipa-
rous women.
Variables included in the pre-specified model Corresponding variables included in the
FMFa-model
Family history of preeclampsia Mother of the woman had preeclampsia
Country of birth Racial origin
Method of conception Method of conception
Gestational length at registration (Based on 1. date of embryo
transfer, 2. early first or early second trimester ultrasound, 3. date
of last menstrual period, and 4. from postnatal assessment)
Gestational length at registration (all based on
first trimester ultrasound)
Maternal age Maternal age
Height Height
Weight Weight
Smoking habits in early pregnancy Smoking habits in early pregnancy
Pre-existing diabetes (Type I and II) Diabetes type I
Diabetes type II
Chronic hypertension Chronic hypertension
Systemic lupus erythematosus Systemic lupus erythematosus
Anti-phospholipid syndrome
Mean arterial pressure (MAP) Mean arterial pressure (MAP)
a Fetal Medicine Foundation
https://doi.org/10.1371/journal.pone.0225716.t002
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The social, reproductive and medical background and medical examination variables from
the first visit in antenatal care are presented in Table 1, stratified into women who did not
develop preeclampsia, women who developed preeclampsia overall and women who devel-
oped preeclampsia with delivery <37 weeks. Women who developed preeclampsia overall
were significantly (p-value of<0.05) older, had higher BMI, longer infertility duration, more
often having assisted reproduction and previous miscarriages compared to women who did
not develop preeclampsia. A family history of hypertension or preeclampsia, being born in
Africa or in Sweden and chronic diseases were more common among women in the pre-
eclampsia group. Medical examinations at first visit displayed increased capillary glucose lev-
els, rates of proteinuria, haemoglobin levels and MAP among women who developed
preeclampsia.
The variable used in the backward selection analyses for prediction of preeclampsia with
delivery at<34,<37 and�37 weeks with 10-fold cross validation are listed in S1 Table.
The receiver operating characteristic (ROC)-curves of the variables ability to predict pre-
eclampsia at<34, <37 and�37 weeks with the three different multivariable methods are
given in Fig 2. Fig 2A–2C include the total study population and Fig 2D–2F present the
restricted population without pregnancies with major malformations or treatment with
aspirin.
The AUC to predict preeclampsia in the total and the restricted populations for the three
outcomes are given in Table 3. Based on the variables included, regardless of any of the three
multivariable methods used for prediction of preeclampsia at<34,<37 or�37 weeks, the
AUC did not reach more than 0.68, indicating uniformly low-to-moderate predictive ability
(Table 3).
The sensitivity at a FPR of 10% for preeclampsia <34 and<37 weeks were superior in the
groups of pre-specified variables. For detection of preeclampsia with delivery�37 weeks, the
best performing models were the pre-specified variables and the backward selection, compared
to the Random forest model (Table 3).
Fig 2. Prediction of preeclampsia in the total study population (A-C) and in the restricted population of pregnancies
without major malformations or treatment with aspirin (D-F) before 34 (A, D), before 37 (B, E) and from 37 (C, F) weeks’
gestation based on pre-specified variables, backward selection and Random forest methods.
https://doi.org/10.1371/journal.pone.0225716.g002
Preeclampsia prediction in nulliparous women
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When using the binary NICE-guidelines risk classification system for identifying women at
risk of preeclampsia in our population, 5.8% of all nulliparous women would be classified as
high risk (screen positive). The detection rate for preeclampsia with delivery <34 weeks would
be 22.2% (95% CI 16.8–28.4), preeclampsia with delivery <37 weeks 19.5% (95% CI 16.1–23.3)
and preeclampsia with delivery�37 weeks 12.2% (95% CI 10.9–13.7), all with a fixed FPR of
about 5.5%. In our best performing models with a chosen FPR of 10%, the detection rate is
higher for preterm and term preeclampsia, but with an overlapping CI for early onset pre-
eclampsia, compared to the NICE-guidelines.
Discussion
Main findings
In this population-based cohort study of 62 562 nulliparous women, we found that using rou-
tinely collected information on well-known and less established or unknown risk factors from
first visit to antenatal care as predictive variables generated a modest predictive capacity for
preeclampsia, irrespective of type of multivariable statistical method used.
The prediction of preeclampsia with delivery <34,<37 or�37 weeks with the three differ-
ent methods was similar with AUC’s of 0.58–0.68. The sensitivities at a fixed 10% FPR varied
between 18.5–30.6%. The performance of the customizable multivariable risk prediction
approach at the FPR of 10% was however significantly better than using the binary NICE-
guidelines for preeclampsia with delivery <37 weeks’ and�37 weeks.
Strengths and limitations
Given the nature of predictive research, this comprehensive set of fine-grained prospectively
routinely collected variables, with generally a minimal level of missing values, collected on a
Table 3. Area under the ROC curve and sensitivity for prediction of preeclampsia with delivery at<34,<37 and�37 weeks’ gestation based on pre-specified vari-
ables, backward selection and Random forest methods.
Total study population
n = 62 562
Restricted study populationc
n = 58 276
Predictive method Area under the
ROCa curve
(95% CI) Sensitivity for 10%
FPRb
(95% CI) Area under the
ROCa curve





Pre-specified variables 0.68 (0.64–0.72) 30.6 (24.5–37.2) 0.67 (0.63-0-72) 28.8 (22.1–36.3)
Backward selection 0.66 (0.62–0.70) 26.9 (21.1–33.3) 0.64 (0.60–0.69) 28.8 (22.1–36.3)
Random forest 0.58 (0.54–0.62) 18.5 (13.6–24.4) 0.57 (0.53–0.62) 17.6 (12.2–24.2)
Prediction of preeclampsia
<37 weeks
Pre-specified variables 0.68 (0.65–0.70) 29.2 (25.2–33.4) 0.68 (0.65-0-71) 29.3 (25.0–34.0)
Backward selection 0.66 (0.63–0.68) 25.8 (22.0–29.8) 0.66 (0.63–0.69) 27.9 (23.6–32.5)
Random forest 0.60 (0.57–0.63) 24.3 (20.6–28.4) 0.60 (0.57–0.62) 21.4 (17.5–25.7)
Prediction of preeclampsia
�37 weeks
Pre-specified variables 0.67 (0.66–0.69) 28.1 (26.3–30.0) 0.67 (0.66–0.68) 27.6 (25.7–29.5)
Backward selection 0.67 (0.66–0.68) 28.2 (26.4–30.1) 0.67 (0.66–0.68) 27.5 (25.6–29.5)
Random forest 0.61 (0.60–0.62) 22.4 (20.7–24.2) 0.62 (0.60–0.63) 22.7 (20.9–24.5)
a ROC: Receiver operating characteristic
b FPR: False-positive rate
c Restricted study population: Pregnancies without major malformations or treatment with aspirin
https://doi.org/10.1371/journal.pone.0225716.t003
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large population represents a distinct strength, increasing the likelihood of accurate prediction
[30]. The use of a database with automatically retrieved information from the computerized
medical record system with standardized data registration, reduced erroneous data entry and
transcription errors. There is no consensus regarding the best method for selection of variables
for a predictive model [31]. The large number of preeclampsia cases enabled use of the full
suite of the 36 variables in the predictive models giving more than ten events per candidate
predictor for preeclampsia with delivery <37 and�37 weeks, and six events for preeclampsia
with delivery <34 weeks. Too few events per candidate predictor has been described as a limi-
tation in risk models for preeclampsia [32].
We internally validated the performance of the three multivariable predictive methods with
10-fold cross validation for the two logistic regression analyses and bootstrap in the Random
forest analyses, preventing over-fitting observed in single-tree approaches. No external valida-
tion was carried out in the scope of our study, however, our inclusion criteria were precisely
defined, facilitating future external validations.
Despite the richness of our data resources, data quality issues are nonetheless a concern.
Potential misclassification of the mainly self-reported variables in the interview with the mid-
wife could have occurred, but since the predictive models were based on routinely collected
information, this would probably reflect the outcome of the models in the clinical setting.
Since this is a retrospective study we could not influence the procedure of blood pressure
examinations, where a potential misclassification bias by measurement errors could have been
introduced. However, midwives have guidelines for conducting blood pressure examinations
and a differential misclassification seems implausible.
Using the ICD-10 diagnosis instead of data from medical records to determine the diagno-
sis of preeclampsia could have introduced misclassification bias of the outcome. In order to
improve the accuracy of the diagnosis, one diagnosis in the inpatient or two diagnoses in the
outpatient register was required. The Swedish version of ICD-10 diagnoses, still define pre-
eclampsia with mandatory proteinuria, which is less sensitive but more specific compared to
current international recommendations of the diagnosis [11, 20]. With few exceptions, previ-
ous predictive models have used or done sensitivity analyses with the same definition [13, 14].
Overall rates of preeclampsia in nulliparous women in our study were consistent with previous
populations from western countries [13, 33].
The effect of aspirin treatment during pregnancy has not been taken into account in
the creation of previous predictive models for preeclampsia [11, 14]. When adjusting
for the assumed effect of aspirin (i.e. the reduced risk of preterm preeclampsia in high
risk women) in one study, the detection rates for preeclampsia were slightly, but not signifi-
cantly reduced [10]. To address this in our study, we made a sensitivity analysis in a
restricted cohort excluding pregnancies with use of aspirin and also major malformations,
without significant alterations of the model’s predictive capacity. This could possibly reflect
the poor selective performance of women for use of aspirin in current Swedish clinical
practice.
Interpretation
In univariate analyses we found that well established risk factors for preeclampsia, such as
increasing BMI and maternal age, assisted reproduction, country of birth, chronic hyperten-
sion, pre-exciting diabetes, chronic kidney disease and family history of preeclampsia were
individually associated with development of preeclampsia [12, 20, 34, 35]. Compared to
women without preeclampsia, women who developed preeclampsia had higher MAP and hae-
moglobin level in early pregnancy in accordance with previous knowledge [13, 36–39].
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Prior studies, using the FMF-model with maternal factors and MAP for mixed parities at a
10% FPR have demonstrated a sensitivity of 47–59% and 37–43% for preterm and term pre-
eclampsia, respectively [10, 15, 21, 40]. Nulliparous women have higher risk of preeclampsia,
and no marker of individual risk based on previous obstetric history [20, 41]. The predictive
capacity of both clinical guidelines and multivariable models are better for parous than nullip-
arous women, and there are only a few predictive studies on nulliparous women separately,
making the evidence gap more pressing for this group [11]. Previous predictive studies on nul-
liparous women, using different inclusion criteria and combinations of maternal factors, dem-
onstrates an AUC of 0.71 and sensitivity of 31–37% with a FPR of 10–11.5% for preeclampsia
overall [11, 13]. For preeclampsia with delivery <37 weeks, an AUC of 0.76 and sensitivity of
34–36% at a FPR of 5–11.5% has been reported, indicating better prediction than in our study
[11, 42].
Defining predictive performance according to how preeclampsia prediction is used in prac-
tice by a clinician, we argue that using a customizable multivariable risk-prediction approach
is superior to the binary NICE classification system, which here results in a fixed false-positive
rate of 5.5%. One advantage of using a multivariable risk-prediction framework to address this
question is that it more flexible to investigator/clinician choices about optimal sensitivity/spec-
ificity. The NICE-guidelines’ predictive capacity for preeclampsia in our cohort of nulliparous
women was inferior compared to our multivariable models tested at a FPR of 10%, in accor-
dance with previous knowledge, but also inferior compared to the NICE-guidelines perfor-
mance in other populations [11, 13]
The generally lower sensitivities in our study compared to other nulliparous populations
could be due to several factors: differences in demographic factors, the population-based rou-
tinely collected material in our study compared to a prospective design with volunteer enrol-
ment, and different methodological approaches. Further, internal validation with bootstrapping
and 10-fold cross validation used in our study generally tend to reduce the risk of overestimating
the predictive capacity of a predictive model [19, 43]. The lower detection rate could also reflect
a need for validation of maternal health care data and possibly improved collection of data.
First trimester screening studies for the risk of preeclampsia in different clinical settings is
emphasised by the International Society for the Study of Hypertension in pregnancy (ISSHP)
[20] and to our knowledge, no previous multivariable predictive study has been evolved or
evaluated in a Swedish setting.
Machine learning methods [23] as Random forest [24] have been demonstrated to yield
accurate prediction in some biomedical applications [25], but in this study resulted in predic-
tion that was less accurate than the logistic regression models. There are many potential expla-
nations for this finding e.g., overreliance on data-based considerations, over-fitting, too many
features unrelated to the outcome that swamp the true signals [44].
Conclusion
The capacity of our multivariable predictive models for preeclampsia with delivery<34, <37
and�37 weeks in nulliparous women was overall modest, but it is worth noting that these
models have advantages as compared to the binary NICE-guidelines risk classification. The
logistic regression models performed better than models using Random forest, indicating that
future work on this topic should continue to incorporate clinical expertise as well as newer pre-
diction approaches.
The models to predict preeclampsia reported here provide a step towards a personalised
risk score for preeclampsia in nulliparous women, a group that would largely benefit from an
improved screening and for whom only a few predictive models have been designed [14].
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To improve overall accuracy and detection of cases, the variables for the clinical model has
to be validated and potentially with the addition of biochemical or biophysical markers.
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